Related references
Note: Only part of the references are listed.Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy
P. A. Jenkins et al.
THORAX (2008)
An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
David E. Griffith et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease
Yoshihiro Kobashi et al.
RESPIRATORY MEDICINE (2007)
Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease
Phung K. Lam et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response
MT Henry et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
CA Benson et al.
CLINICAL INFECTIOUS DISEASES (2003)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus
M Dunne et al.
CLINICAL INFECTIOUS DISEASES (2000)
Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex
DE Griffith et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
